Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9162992 | 0.82 | KMT2A (0.36) | KMT2ANPC1RAB9AMTNR1A | |
| SCHEMBL4191160 | 0.77 | CSF1R (0.34) | — | |
| SCHEMBL2197563 | 0.76 | ALDH1A1 (0.33) | KMT2ANPC1 | |
| SCHEMBL4184795 | 0.74 | TDP1 (0.32) | — | |
| SCHEMBL166209 | 0.74 | KMT2A (0.56) | KMT2AKDM4ERAB9A | |
| SCHEMBL19145900 | 0.74 | KMT2A (0.64) | KMT2ANPC1RAB9A | |
| SCHEMBL8508945 | 0.73 | — | — | |
| SCHEMBL2197438 | 0.72 | KMT2A (0.44) | KMT2ANPC1KDM4ERAB9A | |
| SCHEMBL8735006 | 0.72 | NPSR1 (0.35) | KMT2AKDM4E | |
| SCHEMBL19145899 | 0.71 | KMT2A (0.57) | KMT2ANPC1KDM4ERAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773760-B1 | CATALYTIC METHODS FOR THE PRODUCTION OF (METH)ACRYLATES FROM N-HYDROXYALKYLATED AMIDES | BASF SE (DE) | 2017-01-11 | — | — | EP | disclosed |
| US-8263371-B2 | Catalyzed preparation of (meth)acrylates of N-hydroxyalkylated amides | BASF AKTIENGESELLSCHAFT (DE) | 2012-09-11 | — | — | US | disclosed |
| US-7993886-B2 | Catalyzed preparation of (meth)acrylates of N-hydroxyalkylated amides | BASF AKTIENGESELLSHAFT (DE) | 2011-08-09 | — | — | US | disclosed |
| US-20110171697-A1 | CATALYZED PREPARATION OF (METH)ACRYLATES OF N-HYDROXYALKYLATED AMIDES | BASF AKTIENGESELLSHAFT (DE) | 2011-07-14 | — | — | US | disclosed |
| US-20100285542-A1 | CATALYZED PREPARATION OF (METH)ACRYLATES OF N-HYDROXYALKYLATED AMIDES | BASF AKTIENGESELLSHAFT (DE) | 2010-11-11 | — | — | US | disclosed |
| US-7816485-B2 | Catalyzed preparation of (meth)acrylates of N-hydroxyalkylated amides | BASF AKTIENGESELLSCHAFT (DE) | 2010-10-19 | — | — | US | disclosed |
| EP-1773760-A1 | CATALYTIC METHODS FOR THE PRODUCTION OF (METH)ACRYLATES FROM N-HYDROXYALKYLATED AMIDES | BASF AKTIENGESELLSCHAFT (DE) | 2007-04-18 | — | — | EP | disclosed |
| US-20060036063-A1 | Catalyzed preparation of (meth)acrylates of N-hydroxyalkylated amides | BASF AKTIENGESELLSCHAFT (DE) | 2006-02-16 | — | — | US | disclosed |
| WO-2006012980-A1 | CATALYTIC METHODS FOR THE PRODUCTION OF (METH)ACRYLATES FROM N-HYDROXYALKYLATED AMIDES | BASF AKTIENGESELLSCHAFT (DE) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100285542-A1 | CATALYZED PREPARATION OF (METH)ACRYLATES OF N-HYDROXYALKYLATED AMIDES | NAAA, APEH, NAA15 | KMT2A 518/4885NPC1 4145/4885KDM4E 1449/4885 |
| US-20110171697-A1 | CATALYZED PREPARATION OF (METH)ACRYLATES OF N-HYDROXYALKYLATED AMIDES | NAAA, APEH, NAA15 | KMT2A 518/4885NPC1 4145/4885KDM4E 1449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.